Loading content…
Affiliate-supportedIndependent editorialWe never sell medicationSee how
FDA approvals
2 regulatory events affecting GLP-1 medications in 2025.
FDA reaffirmed enforcement against unauthorized compounded tirzepatide after court ruling — outsourcing facilities ordered to halt production.
Read on fda.gov →FDA approved Ozempic for reducing risk of worsening kidney disease, kidney failure, and CV death in adults with T2D and chronic kidney disease (FLOW trial).
Read on fda.gov →